CREDIT SUISSE AG/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 35 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$421,000
+84.6%
587,000
+119.0%
0.00%
Q1 2020$228,000
-96.3%
268,000
-94.3%
0.00%
-100.0%
Q4 2019$6,224,000
+142.0%
4,704,000
+81.0%
0.01%
+150.0%
Q2 2019$2,572,0002,599,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2020
NameSharesValueWeighting ↓
PenderFund Capital Management Ltd. 9,295,000$12,5493.76%
Context Capital Management, LLC 23,076$22,6121.81%
Weiss Asset Management LP 16,160,000$15,847,9740.94%
Anson Funds Management LP 4,000,000$3,920,0000.79%
SYQUANT CAPITAL SAS 2,000,000$1,9610.77%
DG Capital Management, LLC 1,101,000$1,082,8340.59%
Skaana Management L.P. 2,000,000$1,957,6000.48%
AQR Arbitrage LLC 6,130,000$6,046,0190.27%
OAKTREE CAPITAL MANAGEMENT LP 7,295,000$7,195,0580.10%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$220,6580.04%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders